The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.
The Danish dermatology company Leo Pharma has pumped money into a US based biotech company developing a medical device mainly to be used in treatments of a hair loss disease. It is also the first agreement made from Leo’s newly founded hub in Boston.
With an overwhelming majority, an independent advisory committee under the US drug agency FDA has found that Novo Nordisk’s Leader study provides substantial evidence of cardiovascular risk reduction in treatment with Victoza. The result opens up the opportunity for including the data on the product’s US label.
13 years ago, Novo Nordisk was met with a barrage of criticism for its participation in a trial against the South African government. A new conflict between the industry and the government has now broken out. Novo will have no part of it, but is not shying away from the conflict, stresses press chief.
Lundbeckfonden Ventures’ portfolio company Bonesupport has listed on the Swedish stock market and raised SEK 500 million (about USD 57 million). The IPO puts a period to a busy half year, where two other companies have been sold. New investments are coming up, says managing partner Mette Kirstine Agger.
Novo Nordisk does not only aim to treat obesity, but also potentially to prevent it. The strategy could lead to new types of partnerships, for instance with the food industry, says CEO Lars Fruergaard Jørgensen.
Novo Nordisk fører an i jagten på at udvikle medicin, som kan smelte kilo af overvægtige kroppe. Spritnye resultater for GLP-1-analogen Semaglutid viser de første gode takter for medicinalkoncernens næste fedmehåb. (opdateret)
Om Lundbeck vil forsøge en tredje gang at få udvidet indlægssedlen på antidepressivet Trintellix i USA er endnu uvist, siger forskningsdirektør Anders Gersel Pedersen for hvem, nattens afslag fra FDA ikke var en fuldstændig overraskelse.